Anti-CD28 Antibody-Initiated Cytokine Storm in Canines.
Rosinski, S.L., Storb, R., Strong, R.K., Sale, G.E., Stone, D.M., Gewe, M.M., Friend, D.J., Abrams, V.K., Randolph-Habecker, J., Graves, S.S.(2015) Transplant Direct 1
- PubMed: 25988188 
- DOI: https://doi.org/10.1097/TXD.0000000000000516
- Primary Citation of Related Structures:  
4R0L - PubMed Abstract: 
CD28 signal blockade following T cell receptor activation is under intense investigation as a tolerance-inducing therapy for transplantation. Our goal is to produce a CD28-specific reagent as a therapy for the prevention of graft rejection and graft-versus-host disease in the canine model of allogeneic hematopoietic cell transplantation (HCT).
Organizational Affiliation: 
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Washington, 98109 ; Department of Medicine, University of Washington, Seattle, Washington, 98195.